163 related articles for article (PubMed ID: 11400121)
1. c-erbB-2 (HER-2/neu) gene amplification is a better indicator of poor prognosis than protein over-expression in operable breast-cancer patients.
Riou G; Mathieu MC; Barrois M; Le Bihan ML; Ahomadegbe JC; Bénard J; Lê MG
Int J Cancer; 2001 Jul; 95(4):266-70. PubMed ID: 11400121
[TBL] [Abstract][Full Text] [Related]
2. Prognostic and predictive value of c-erbB-2 (HER-2/neu) gene amplification in human breast cancer.
Tsuda H H
Breast Cancer; 2001; 8(1):38-44. PubMed ID: 11180764
[TBL] [Abstract][Full Text] [Related]
3. p185 overexpression in 220 samples of breast cancer undergoing primary surgery: comparison with c-erbB-2 gene amplification.
Dalifard I; Daver A; Goussard J; Lorimier G; Gosse-Brun S; Lortholary A; Larra F
Int J Mol Med; 1998 May; 1(5):855-61. PubMed ID: 9852307
[TBL] [Abstract][Full Text] [Related]
4. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer.
Paterson MC; Dietrich KD; Danyluk J; Paterson AH; Lees AW; Jamil N; Hanson J; Jenkins H; Krause BE; McBlain WA
Cancer Res; 1991 Jan; 51(2):556-67. PubMed ID: 1670762
[TBL] [Abstract][Full Text] [Related]
5. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.
Press MF; Bernstein L; Thomas PA; Meisner LF; Zhou JY; Ma Y; Hung G; Robinson RA; Harris C; El-Naggar A; Slamon DJ; Phillips RN; Ross JS; Wolman SR; Flom KJ
J Clin Oncol; 1997 Aug; 15(8):2894-904. PubMed ID: 9256133
[TBL] [Abstract][Full Text] [Related]
6. Prognosis of breast cancer: evidence for interaction between c-erbB-2 overexpression and number of involved axillary lymph nodes.
Mittra I; Redkar AA; Badwe RA
J Surg Oncol; 1995 Oct; 60(2):106-11. PubMed ID: 7564375
[TBL] [Abstract][Full Text] [Related]
7. neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group.
Andrulis IL; Bull SB; Blackstein ME; Sutherland D; Mak C; Sidlofsky S; Pritzker KP; Hartwick RW; Hanna W; Lickley L; Wilkinson R; Qizilbash A; Ambus U; Lipa M; Weizel H; Katz A; Baida M; Mariz S; Stoik G; Dacamara P; Strongitharm D; Geddie W; McCready D
J Clin Oncol; 1998 Apr; 16(4):1340-9. PubMed ID: 9552035
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of c-erbB-2/neu amplification and epidermal growth factor receptor (EGFR) in primary breast cancer and their relation to estradiol receptor (ER) status.
Torregrosa D; Bolufer P; Lluch A; López JA; Barragán E; Ruiz A; Guillem V; Munárriz B; García Conde J
Clin Chim Acta; 1997 Jun; 262(1-2):99-119. PubMed ID: 9204213
[TBL] [Abstract][Full Text] [Related]
9. [Her-2 amplification and p185 expression in invasive breast cancer cells in women].
Titi S
Ann Acad Med Stetin; 2006; 52(2):5-12. PubMed ID: 17633393
[TBL] [Abstract][Full Text] [Related]
10. What's new in breast cancer? Molecular perspectives of cancer development and the role of the oncogene c-erbB-2 in prognosis and disease.
Dawkins HJ; Robbins PD; Smith KL; Sarna M; Harvey JM; Sterrett GF; Papadimitriou JM
Pathol Res Pract; 1993 Dec; 189(10):1233-52. PubMed ID: 7910395
[TBL] [Abstract][Full Text] [Related]
11. Cyclin E amplification, over-expression, and relapse-free survival in HER-2-positive primary breast cancer.
Luhtala S; Staff S; Tanner M; Isola J
Tumour Biol; 2016 Jul; 37(7):9813-23. PubMed ID: 26810187
[TBL] [Abstract][Full Text] [Related]
12. C-erbB-2 onco-protein expression in breast cancer: relationship to tumour characteristics and short-term survival in Universiti Kebansaan Malaysia Medical Centre.
Sharifah NA; Lee BR; Clarence-Ko CH; Tan GC; Shiran MS; Naqiyah I; Rohaizak M; Fuad I; Tamil AM
Asian Pac J Cancer Prev; 2008; 9(4):663-70. PubMed ID: 19271345
[TBL] [Abstract][Full Text] [Related]
13. Relevance of p185 HER-2/neu oncoprotein quantification in human primary breast carcinoma.
Bermont L; Algros MP; Baron MH; Adessi GL
Breast Cancer Res Treat; 2000 Sep; 63(2):163-9. PubMed ID: 11097092
[TBL] [Abstract][Full Text] [Related]
14. HER-2/neu gene amplification by fluorescence in situ hybridization allows risk-group assessment in node-negative breast cancer.
Harbeck N; Ross JS; Yurdseven S; Dettmar P; Pölcher M; Kuhn W; Ulm K; Graeff H; Schmitt M
Int J Oncol; 1999 Apr; 14(4):663-71. PubMed ID: 10087312
[TBL] [Abstract][Full Text] [Related]
15. Long-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testing.
Schmidt M; Lewark B; Kohlschmidt N; Glawatz C; Steiner E; Tanner B; Pilch H; Weikel W; Kölbl H; Lehr HA
Breast Cancer Res; 2005; 7(2):R256-66. PubMed ID: 15743506
[TBL] [Abstract][Full Text] [Related]
16. [Overexpression of c-erbB-2 gene product is associated with poor prognosis factors in breast carcinoma].
Cianga C; Cianga P; Cozma L; Diaconu C; Carasevici E
Rev Med Chir Soc Med Nat Iasi; 2003; 107(2):349-53. PubMed ID: 14755939
[TBL] [Abstract][Full Text] [Related]
17. The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer.
Bull SB; Ozcelik H; Pinnaduwage D; Blackstein ME; Sutherland DA; Pritchard KI; Tzontcheva AT; Sidlofsky S; Hanna WM; Qizilbash AH; Tweeddale ME; Fine S; McCready DR; Andrulis IL
J Clin Oncol; 2004 Jan; 22(1):86-96. PubMed ID: 14701769
[TBL] [Abstract][Full Text] [Related]
18. Genetic alterations in early-onset invasive breast carcinomas: correlation of c-erbB-2 amplification detected by fluorescence in situ hybridization with p53 accumulation and tumor phenotype.
Fiche M; Avet-Loiseau H; Heymann MF; Moussaly F; Digabel C; Joubert M; Classe JM; Dravet F; Fumoleau P; Ross J; Maugard CM
Int J Cancer; 1999 Oct; 84(5):511-5. PubMed ID: 10502729
[TBL] [Abstract][Full Text] [Related]
19. Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer.
Kallioniemi OP; Holli K; Visakorpi T; Koivula T; Helin HH; Isola JJ
Int J Cancer; 1991 Nov; 49(5):650-5. PubMed ID: 1682277
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors.
Rilke F; Colnaghi MI; Cascinelli N; Andreola S; Baldini MT; Bufalino R; Della Porta G; Ménard S; Pierotti MA; Testori A
Int J Cancer; 1991 Aug; 49(1):44-9. PubMed ID: 1678734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
